Antimicrobial stewardship

Pharmacotherapy

Volumn 27, Issue 10 II, 2007, Pages

  Rybak, Michael J ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Antibiotic; Antimicrobial; Methicillin resistant Staphylococcus aureus; MRSA; Pathogen; Resistance

Indexed keywords

CEFDITOREN; CEFEPIME; CEFPODOXIME; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DIRITHROMYCIN; ERTAPENEM; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LINEZOLID; LOMEFLOXACIN; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SPARFLOXACIN; TELITHROMYCIN; TEMAFLOXACIN; TIGECYCLINE; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; CONFERENCE PAPER; DECISION SUPPORT SYSTEM; DRUG PROGRAM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; UNITED STATES;

EID: 34948845660     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.10part2.131s     Document Type: Conference Paper

References (16)

1. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003;289:885-8.
2. Bosso JA, Mauldin PD. Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:2106-12.
3. Lautenbach E, Larosa LA, Kasbekar N, et al. Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use. Arch Intern Med 2003;163:601-5.
4. Paterson DL. The role of antimicrobial management programs in optimizing antibiotic prescribing within hospitals. Clin Infect Dis 2006;42(suppl 2):S90-5.
5. United States Food and Drug Administration. Food and Drug Administration drug and device product approvals. Available from http://www.fda.gov/cder/da/ddpa.htm. Accessed January 8, 2007.
6. Fishman N. Antimicrobial stewardship. AmJ Med 2006;119(6 suppl 1):S53-61.
7. Centers for Disease Control and Prevention. 12 steps to prevent antimicrobial resistance among hospitalized adults. Available from http://www.cdc.gov/drugresistance/healthcare/ha/12steps_HA.htm. Accessed January 8, 2007.
8. Sunenshine RH, Liedtke LA, Jernigan DB, Strausbaugh LJ. Role of infectious diseases consultants in management of antimicrobial use in hospitals. Clin Infect Dis 2004;38:934-8.
9. Owens RC Jr, Fraser GL, Stogsdill P. Antimicrobial stewardship programs as a means to optimize antimicrobial use: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2004;24:896-8.
10. Dellit TH. Antimicrobial stewardship. Presented at the 43rd annual meeting of the Infectious Diseases Society of America, San Francisco, CA, October 6-9, 2005.
11. MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 2005;18:638-56.
12. Arnold FW, McDonald LC, Smith RS, Newman D, Ramirez JA. Improving antimicrobial use in the hospital setting by providing usage feedback to prescribing physicians. Infect Control Hosp Epidemiol 2006;27:378-82.
13. Warren DK, Hill HA, Merz LR, et al. Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant gram-negative bacteria among intensive care unit patients. Crit Care Med 2004;32:2450-6.
14. Pestotnik SL. Expert clinical decision support systems to enhance antimicrobial stewardship programs: insights from the society of infectious diseases pharmacists. Pharmacotherapy 2005;25:1116-25.
15. Richards MJ, Robertson MB, Dartnell JG, et al. Impact of a web-based antimicrobial approval system on broad-spectrum cephalosporin use at a teaching hospital. Med J Aust 2003;178:386-90.
16. Drew RH, Kawamoto K, Adams MB. Information technology for optimizing the management of infectious diseases. Am J Health Syst Pharm 2006;63:957-65.